Lehman Upgrades Regeneron Pharmaceuticals

Analyst Jim Birchenough upgrades on improving prospects for the company's VEGF TRAP in Age-related Macular Degeneration and Oncology, and prospects for improved data flow over the next 12 months

Lehman Brothers upgraded Regeneron Pharmaceuticals (REGN ) to overweight from equal-weight. It also raised its $9 price target to $19.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.